News

Pliant Therapeutics' Promising Data on PLN-101095 in Trials

Pliant Therapeutics' Promising Data on PLN-101095 in Trials

Exciting Developments in Cancer Treatment with PLN-101095

Pliant Therapeutics, Inc. (Nasdaq: PLRX) has recently unveiled interim findings from its groundbreaking clinical trial involving PLN-101095. This investigational treatment has shown promise in patients who have advanced solid tumors that have not responded to immune checkpoint inhibitors (ICIs). The trial aims to assess the efficiency of PLN-101095 when administered alongside pembrolizumab, a well-known immunotherapy drug.

Clinical Trial Highlights

The results from the trial are noteworthy. Out of the ten patients who were administered PLN-101095, four demonstrated significant anti-tumor activity. Specifically, one patient achieved a complete response (CR), and three others achieved partial responses (PR), indicating a robust efficacy in this seriously ill population. These outcomes exceeded expectations given the challenging nature of the tumors treated, which included types such as cholangiocarcinoma, melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer (NSCLC).

Response and Treatment Duration

Patients in the trial generally showed prolonged responses, with a median treatment duration of around 15 months. This is particularly encouraging considering the patients were heavily pretreated and resistant to existing therapies. Additionally, a substantial percentage of these patients experienced stable disease or tumor shrinkage, reflecting the potential of PLN-101095 to offer new treatment options.

Mechanism of Action

PLN-101095 functions as a dual selective inhibitor targeting integrins ?v?8 and ?v?1. This mechanism is designed to disrupt the immunosuppressive microenvironment created by transforming growth factor-beta (TGF-?) in tumors, which often leads to resistance against immunotherapy. By blocking these integrins, PLN-101095 aims to stimulate immune responses, allowing for improved infiltration of immune cells into the tumor.

Patient Response Analysis

An interesting observation from the trial is the increase in plasma interferon gamma (IFN-?) levels among responding patients. The significant rise in IFN-?, observed at levels 4 to 13 times higher than baseline, serves as a potential biomarker for the drug's effectiveness. On the contrary, non-responders showed no meaningful increases, further validating the potential of IFN-? as an indicator of treatment success.

Future Directions

Encouraged by these interim results, Pliant Therapeutics is gearing up to expand the development of PLN-101095. A Phase 1b indication expansion trial is on the horizon, set to explore its functionality in NSCLC and other tumor types where integrin inhibition shows great promise.

Expert Insights

Dr. Bernard Coulie, CEO of Pliant, expressed optimism about these findings, stating that the responses seen in such difficult-to-treat tumors reinforce the potential for PLN-101095 to revolutionize treatment for patients with limited options. Furthermore, Dr. Manish Sharma, Co-Director of Clinical Research, highlighted the potential of this innovative approach to address significant unmet medical needs.

Pliant's Broader Vision

Beyond PLN-101095, Pliant Therapeutics is dedicated to advancing their integrin-based therapeutic platform, which has broad applications in various disease areas. Their ongoing work in targeted drug delivery utilizing integrin receptors holds promise for improving treatment outcomes across several conditions.

About Pliant Therapeutics, Inc.

Pliant Therapeutics stands at the forefront of creating integrin-based therapies designed to address complex medical challenges. With their leading candidate, PLN-101095, they aim to create new benchmarks in cancer treatment, while their innovative research could potentially transform how drugs are delivered and utilized in various medical fields.

Frequently Asked Questions

What is PLN-101095 and how does it work?

PLN-101095 is an oral small molecule that inhibits integrins ?v?8 and ?v?1, aimed at disrupting the immunosuppressive tumor environment to enhance anti-tumor responses.

What were the results of the Pliant clinical trial?

The trial revealed one complete response and three partial responses in patients, showcasing the drug's potential effectiveness in ICI-refractory tumors.

How long were patients treated in the trial?

Patients were treated for a median duration of approximately 15 months, indicating persistent efficacy of the treatment.

What is the next step for PLN-101095?

Pliant plans to initiate a Phase 1b trial to further investigate PLN-101095's effects in NSCLC and other tumor types, expanding upon the promising initial results.

How does Pliant Therapeutics plan to utilize their integrin-based platform?

Pliant aims to develop targeted drug delivery systems that can enhance treatment precision across various diseases, taking advantage of integrin receptors to direct drug actions effectively.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 34

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 55

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 183

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 67

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 147

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 0

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 65

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading

Top 5 Most Recently Viewed Articles

Wesdome Gold Mines Pursues Significant Share Repurchase Plan

Updated Category News Views 220

Wesdome Gold Mines Initiates Share Buyback Program Wesdome Gold Mines Ltd. (TSX: WDO, OTCQX: WDOFF) is excited to unveil its plan for a Normal Course Issuer Bid (NCIB), which has just received approval from its board of directors and is pending final consent from the Toronto Stock Exchange (TSX). This strategic initiative allows the company to buy back a substantial 2% of...

Continue Reading
Zillow Faces August Class Action Deadline: Investor Alert

Updated Category News Views 51

Investor Tensions Rise Ahead of Zillow's Legal Deadline August 10, 2026—mark it down. That's your last call to jump into the fray with the class action suit against Zillow Group, Inc. (NASDAQ: ZG, Z), should you have skin in the game. We're talking investors who bought into Zillow from February 11, 2025, through May 7, 2026. Yeah, 'investor alert' might as well be...

Continue Reading
Explore Opportunities in the 2025 Global Omics Sciences Contest

Updated Category News Views 214

Unveiling the 2025 Mammoth International Contest on Omics Sciences Guided by esteemed organizations like UNESCO, the 2025 Mammoth International Contest on Omics Sciences offers young scientists an incredible platform to showcase their talents and innovative ideas. This initiative is proudly co-organized by BGI Research and the Jinze Charitable Foundation, unveiling a new...

Continue Reading
Navigating Disagreements: Jeff Bezos' Unique Leadership Style

Updated Category News Views 544

Embracing Different Perspectives: Jeff Bezos' Approach In a recent discussion, Jeff Bezos, the founder of Amazon.com, Inc. (NASDAQ: AMZN), reflected on his distinctive methodology for making decisions quickly and effectively. He believes that fostering an environment of trust and open dialogue is essential for overcoming disagreements. The Philosophy of Disagree and...

Continue Reading
Exploring Philanthropy's Impact on the U.S.-Mexico Border

Updated Category News Views 273

Unveiling Border Briefs in San Diego Recently, the U.S.-Mexico Border Philanthropy Partnership (BPP) introduced the Border Briefs series during an impactful event named Voices and Visions from the Border: A Funder Dialogue. This gathering was held at the San Diego Central Library, aiming to highlight the dynamic role that philanthropy plays in addressing challenges and...

Continue Reading